Conclusion: For both aGVHD and cGVHD, the anti-GVHD effect with relapse-neutral effect of ATG appears to be mediated by antibodies to antigens expressed on naive T cells (both CD4 and CD8), EM CD4 T cells and regulatory NK cells. This is the first step towards identifying the antibody(ies) within ATG important for the anti-GVHD effect without impacting relapse. : USING THE PRI-MATE GVHD MODEL TO DETERMINE THE ROLE THAT SIROLIMUS PLAYS  IN GVHD The Rhesus Macaque GvHD Model is uniquely able to support a mechanistic dissection of the contribution that individual immunomodulating agents make to GvHD prevention, in a clinically relevant primate system. In this study, we determined the primary mechanism by which sirolimus prevents GvHD in primates. Rhesus macaques underwent MHC-mismatched HSCT while receiving sirolimus monotherapy (sirolimus trough5-15 ng/mL). Recipients exhibited modestly prolonged survival compared to untreated controls (MST . 19 days versus 6.5 days in controls).
DISSECTING THE MECHANISMS OF GVHD CONTROL
Sirolimus markedly inhibited T cell proliferation in transplanted animals. Thus, while CD4+ and CD8+ T cells expanded by as much as 300-fold and 2000-fold, respectively, in the absence of immunoprophylaxis, in sirolimus-treated animals, the accumulation of these cells was significantly blunted, with their expansion being only 4-and 3.6-fold, respectively compared to the post-TBI nadir. Consistent with this marked impact on T cell proliferation, sirolimus-treated recipients also better controlled the upregulation of the proliferation marker Ki-67 on CD4+ or CD8+ T cell subpopulations. Thus, while untreated recipients upregulated Ki-67 expression by as much as 10-fold after engraftment, (with . 80-98% of both CD4+ and CD8+ T cells expressing high levels of Ki-67 post-transplant versus 5-10% pre-transplant) sirolimus-treated recipients displayed blunted Ki-67 expression (with an average of only 29% of both CD4+ and CD8+ T cells expressing high levels of Ki-67 post-transplant).
While the impact of sirolimus on T cell proliferation was profound, its impact on the expression of CD127 (the IL-7Ra), a marker of T cell activation, was small. Thus, similar to the untreated control animals, who demonstrated a total loss of CD127 in the context of severe clinical GvHD, up to 60% of CD8+ T cells in sirolimustreated recipients down-regulated CD127, consistent with breakthrough activation and functional maturation of these cells despite mTOR inhibition.
These results indicate that the predominant effect of sirolimus during primate GvHD prophylaxis is its striking ability to inhibit T cell proliferation. These results imply that therapies that are added to sirolimus to achieve multimodal GvHD prevention should be directed at inhibiting T cell activation and function rather than proliferation, in order to target non-redundant pathways of alloimmune activation during GvHD control. HiCy treatment on day 3 post-BMT dampened proliferation of alloreactive T cells on days 4, 7, 14 and 21 (p \ 0.05; HiCy vs DT-treated chimeras and controls). Treg depletion in HiCy recipients promoted donor T-cell expansion, suggesting that Tregs were vital to the protective action of HiCy. GVHD was more severe in Treg-depleted chimeras (P\0.05, compared to controls) and absent in HiCy-treated animals (P \ 0.01, HiCy vs PBS-and DT-treated chimeras). HiCy-mediated protection was offset by Treg ablation, resulting in increased morbidity and mortality. The development of GVHD in untreated and Treg-depleted HiCy-treated chimeras was associated with emergence of CD4 + Foxp3 + IFN-g-producing cells. To overcome heterogeneity in human Foxp3 expression, we examined three phenotypically and functionally distinct Treg subsets based on expression of CD25, Foxp3 and CD45RA. We found that patients with acute GVHD had a substantial increase in the CD25 ++ CD45RA 
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